#adalimumab
LightNews LightNews
ophthalmology.bsky.social
Ophthopedia Update: Weekly Journal Update — February 11, 2026: Adalimumab vs immunosuppressive drugs for uveitis, retinal vascular occlusions and dementia, the gut microbiome and AMD, regenerative cell therapy for corneal edema, systemic drugs and maculopathy. #Ophthalmology #News
Weekly Journal Update — February 11, 2026
Adalimumab vs immunosuppressive drugs for uveitis, retinal vascular occlusions and dementia, the gut microbiome and AMD, regenerative cell therapy for corneal edema, systemic drugs and maculopathy.
dlvr.it
February 11, 2026 at 8:22 PM
aga-gastro.bsky.social
Three-year follow-up data from the LADI RCT showed that over one-third of patients with #CrohnsDisease in stable remission who initiated adalimumab de-escalation were on a de-escalated adalimumab interval at year three.
🔗 https://ow.ly/u7e850YbPCp
February 11, 2026 at 5:30 PM
acr-journals.bsky.social
A 54-year-old woman with rheumatoid arthritis controlled with methotrexate and adalimumab presented with subacute abdominal distension, constipation, and decreased urinary frequency. Abdominal CT showed extensive omental and mesenteric nodules, concerning for peritoneal carcinomatosis
CT abdomen/pelvis shows Ascites (red arrows), mesenteric nodularity (green arrows), and retroperitoneal lymphadenopathy (purple arrows). top, Lymph node biopsy showing extensive granulomatous inflammation (red circles) and numerous giant cells (green arrows) on low magnification (Hematoxylin and eosin stain). bottom, Lymph node biopsy showing extensive granulomatous inflammation (red circles) and numerous giant cells (green arrows) high magnification (Hematoxylin and eosin stain).
February 9, 2026 at 5:16 PM
bild.bsky.social
Ayrıca, adalimumab ilacı sonrası beyaz kan hücresi aktivitesine bağlı kan sinyali bulundu. Bu bulgular, sedef tedavisinin gelecekte daha kişiye özel hale gelmesine olanak sağlayabilirmiş.
February 9, 2026 at 1:20 PM
linchi97.bsky.social
Adalimumab Drug Market Size, Share, Trends, Report 2035 www.marketresearchfuture.com/reports/adal...
Adalimumab Drug Market Size, Share, Trends, Report 2035
Adalimumab Drug Market is expected to reach USD 38.02 Billion by 2035, growing at a CAGR of 3.78% during the forecast period 2025-2035.
www.marketresearchfuture.com
February 9, 2026 at 7:07 AM
lori3030.bsky.social
- Airsupra – asthma rescue inhaler
- Abrilada – rheumatoid arthritis (adalimumab biosimilar)
- Genotropin – growth hormone deficiency
February 8, 2026 at 2:13 AM
matthewcort.land
19 of the 43 drugs on the Trump-skinned GoodRx site that is TrumpRx.gov already have generic equivalents. In most cases, the generic is dramatically cheaper.

www.patreon.com/posts/150062...
Table: "TrumpRx Brand Price vs. Generic," comparing 20 drugs on TrumpRx that have generic equivalents. Columns: TrumpRx Drug, Generic Name, TrumpRx Price, Generic Price. Sorted by TrumpRx price descending. Tikosyn (dofetilide) $336.00 vs ~$19. Vfend (voriconazole) $306.98 vs ~$69. Protonix (pantoprazole) $200.10 vs ~$9. Pristiq (desvenlafaxine) $200.10 vs ~$20. Azulfidine En-Tabs (sulfasalazine DR) $130.80 vs ~$12. Zyvox (linezolid) $122.74 vs ~$32. Azulfidine (sulfasalazine) $99.60 vs ~$9. Chantix (varenicline) $94.87 vs ~$37. Zarontin (ethosuximide) $71.73 vs ~$32. Colestid (colestipol) $67.80 vs ~$25. Cortef (hydrocortisone) $45.90 vs ~$10. Toviaz (fesoterodine) $43.50 vs ~$32. Lopid (gemfibrozil) $39.60 vs ~$24. Cleocin (clindamycin) $36.56 vs ~$11. Levoxyl (levothyroxine) $36.00 vs ~$4. Diflucan (fluconazole) $14.06 vs ~$4. Abrilada (adalimumab) $207.60 vs ~$350+ — Abrilada is itself a biosimilar; other adalimumab biosimilars cost ~$350+. Cytomel (liothyronine) $6.00 vs ~$25 — generic costs more. Medrol (methylprednisolone) $3.15 vs ~$4 — generic costs more. Viracept (nelfinavir) $607.20 vs ~$1,200 — generic costs more. Generic prices are approximate GoodRx coupon prices, February 2026.
February 6, 2026 at 6:43 PM
franqzisco.bsky.social
AH VALE ADALIMUMAB COÑO.
February 6, 2026 at 1:28 PM
lamuertaviva.bsky.social
Teherín Teherán
ca 14 días el adalimumab
Obi obi
Pinchar pinchar
Ca 14 días el adalimumab
O tus tripas se van a esfaratá
Ca 14 días el adalimumab

💃🏽
February 6, 2026 at 1:27 PM
lamuertaviva.bsky.social
Casi se me olvida pincharme el adalimumab 🤡👌🏽
February 6, 2026 at 1:00 PM
analysisgroup.com
In a new Law360 piece, Pavel Darling, Andrée-Anne Fournier, and Michael Carson examine how PBM formulary decisions, FDA guidance, and private-label biosimilars are shaping competition between Humira and adalimumab biosimilars. www.analysisgroup.com/news-and-eve...
February 5, 2026 at 6:28 PM
psoriasisclub.org
This study assessed Humira (adalimumab) efficacy and drug survival in routine Australian clinical practice on patients with psoriasis.

#Psoriasis

psoriasisclub.org/thread-8414....
Real-world evidence in Australian psoriasis patients using Humira
psoriasisclub.org
February 3, 2026 at 11:53 AM
ophthalmology.bsky.social
Ophthopedia Update: Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trial: Noninfectious uveitis (NIU) is a group of sight-threatening diseases characterized by intraocular inflammation.… #Ophthalmology #Ophthotwitter #Scicomm
Adalimumab, Anakinra and Tocilizumab in patients with non-infectious Uveitis: A multicenter randomized controlled trial
Noninfectious uveitis (NIU) is a group of sight-threatening diseases characterized by intraocular inflammation. Uveitis can be associated with a systemic condition or isolated to the eye.1 The prevalence of NIU is estimated between 10.5 and 52 cases per 100 000 inhabitants, and accounts for 10-15% of all definitive vision losses in industrialized countries, therefore requiring prompt management.2,3 The main therapeutic goals in NIU are induction and maintenance of clinical remission, aiming to prevent ocular complications and notably permanent blindness.
dlvr.it
February 3, 2026 at 10:19 AM
ucsfchildrens.bsky.social
Discontinuing the uveitis & arthritis drug adalimumab led to higher rates of recurrence in patients with juvenile idiopathic arthritis-associated uveitis, a study finds. The good news? "Disease control can be regained after restarting treatment,” Dr. Nisha Acharya says. https://ucsfh.org/4qGioxZ
UCSF-led Clinical Trial of Patients with Juvenile Arthritis-associated Uveitis Validates Continued Treatment with Adalimumab - UCSF MedConnection
In a study published last January in The Lancet, UCSF researchers sought to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis by c...
ucsfh.org
February 2, 2026 at 11:05 PM
jama.com
A patient receiving adalimumab for rheumatoid arthritis had ulcerated plaques on the anterior and lateral aspects of the neck, upper chest, and nape and erythroderma on the dorsum of the hands.

What is the diagnosis, and what would you do next?

ja.ma/3NOe7Kq
Article from JAMA, published December 29, 2025, titled "A Woman With Rheumatoid Arthritis and Vesicular Rash." Includes photos of rash on patient's neck, ear, and hands. Possible next steps include discontinuing adalimumab or prescribing prednisone@60.
January 31, 2026 at 2:00 PM
acr-journals.bsky.social
January 2026 Arthritis & Rheumatology Clinical Connections:

• Effectiveness of Abatacept vs Adalimumab in HLA-DRB1 Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis
• Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation

acr.tw/3Z2UvEP
Effectiveness of Abatacept vs Adalimumab in HLA-DRB1 Shared Epitope Positive and Negative Patients With Rheumatoid Arthritis Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
January 30, 2026 at 6:10 PM
vasculitides.bsky.social
Adalimumab-induced changes in NK cells phenotype, receptors and functions after clinical remission of Behcet's uveitis
Adalimumab-induced changes in NK cells phenotype, receptors and functions after clinical remission of Behçet's uveitis - PubMed
BU and AS share similar NK activation pathways. In BU, adalimumab rebalances NK activating/inhibitory receptors (increased NKG2A with persistent NKG2D), contracts cytotoxic effector cells, and shifts toward an exhausted-like phenotype in parallel with clinical improvement, supporting NK-receptor bal …
pubmed.ncbi.nlm.nih.gov
January 29, 2026 at 8:17 PM
vasculitides.bsky.social
Minimizing missed latent tuberculosis infection under adalimumab: real-world data from a BCG-vaccinated cohort
Minimizing missed latent tuberculosis infection under adalimumab: real-world data from a BCG-vaccinated cohort - PubMed
LTBI screening and prophylaxis reduce but do not eliminate TB risk under ADA. Combined TST/IGRA and periodic re-evaluation may reduce missed cases in BCG-vaccinated populations.
pubmed.ncbi.nlm.nih.gov
January 28, 2026 at 3:22 PM
kosmolink.bsky.social
Ich 🤢🤮 jetzt übrigens schon, wenn ich nur die Verpackung vom Selbstschussapparat sehe.
Das Adalimumab ist nicht wirklich mein Medikament 🤮
January 27, 2026 at 7:41 AM
acr-journals.bsky.social
Seq study of a patient with chronic recurrent multifocal osteomyelitis identified OGFRL1 deficiency as genetic cause, with a subsequent mouse model suggesting pathogenesis by promoting osteoclastogenesis. TNFi therapy led to clinical improvement

Arthritis & Rheumatology
doi.org/10.1002/art....
The clinical and genetic information of the patient with OGFRL1 mutation. (A) Imaging manifestations of the patient, uneven flattening of the C3, C6, and C7 vertebral bodies, deformed, malpositioned, and displaced posteroinferiorly C6-C7 disc, compressing the thecal sac (Left image); Multiple patchy T1 hypointense/T2-FS hyperintense lesions in bilateral iliac bones (para-articular), pubic bones, S1–S2, and right proximal femur, some with marginal T2 hypointensity, and bilateral sacroilitis with irregular joint spaces (Middle image); Multiple patchy irregular T2 hyperintense signals in right distal femoral and proximal tibial metaphyses (Right image). (B) Clinical improvement with TNF inhibitor therapy. Pre_treatment: The imaging manifestations of the patient before the regular treatment of adalimumab. [...] Post_treatment: The imaging manifestations of the patient after the administration of adalimumab according to the lesions above.
January 26, 2026 at 1:38 PM
acr-journals.bsky.social
A 59 y/o man with history of lumbar spondylosis & spinal surgeries presented with acute-on-chronic lower back pain & persistent bilateral radicular symptoms. MRI revealed multilevel degenerative changes, spinal stenosis, & diffuse lytic lesions

Case report in ACROR
doi.org/10.1002/acr2...
(A) Lumbar MRI with T1 (1) and STIR (2) imaging, showing diffuse lytic lesions worst on L3-L5. (B) Clinical and treatment timeline. This timeline illustrates the key events, including the onset of musculoskeletal symptoms, imaging evaluations, and initiation of immunosuppressive therapies. (C) Serial PET imaging demonstrating disease activity over time. Coronal and axial PET scan views (1) at symptom onset (0 months), demonstrating widespread small foci of the hypermetabolism in the axial skeleton, borderline mild diffuse hypermetabolism of the spleen, and intense hypermetabolism in small cervical, internal mammary, and right inguinal lymph nodes, the distal left external iliac lymph node, and the inferior parotid gland; (2) at 12 months, following initiation of glucocorticoids and methotrexate, showing partial metabolic response with decreased FDG uptake in previously involved areas; and (3) at 22 months, after escalation to adalimumab, revealing near-complete resolution of metabolic activity, correlating with clinical improvement and radiographic remission. (D) Histopathology from the computed tomography–guided bone biopsy of the left iliac bone, right iliac crest, and proximal left femur. (1) Granulomas surrounded by a rim of lymphocytes (right); bony trabecula (left). (2) Granuloma with central fibrinoid necrosis (upper left), giant cell (lower right), bony trabecula (upper right), and rim of lymphocytes (lower left). (3) Granulomas replaced by fibrous nodules.
January 25, 2026 at 1:27 PM
sarcoidosenl.bsky.social
Immunosuppressiva remmen het afweersysteem en worden gebruikt bij o.a. sarcoïdose. Voorbeelden: prednison, azathioprine, MMF, methotrexaat, adalimumab en infliximab. Ze verhogen het risico op infecties. Meer info: sarcoidose.nl/bibliotheek/...

#woordenlijst #sarcoidose
January 25, 2026 at 9:01 AM
rheumnow.bsky.social
Are JAK Inhibitors Better at Pain Relief in RA?

Among RA patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial data.

buff.ly/X86Xd1L
January 23, 2026 at 10:01 PM
vitaminrush.bsky.social
Pharmacist Strategies for Navigating Supplement Use in Patients on TNF Inhibitors

https://www.vitaminrush.com/292827/pharmacist-strategies-for-navigating-supplement-use-in-patients-on-tnf-inhibitors/

Tumor necrosis factor (TNF) inhibitors, including adalimumab (Humira; AbbVie), etanercept …
Pharmacist Strategies for Navigating Supplement Use in Patients on TNF Inhibitors - Vitamin Rush
Tumor necrosis factor (TNF) inhibitors, including adalimumab (Humira; AbbVie), etanercept (Enbrel; Amgen), and infliximab (Remicade; Janssen Biotech, Inc),
www.vitaminrush.com
January 23, 2026 at 6:40 PM
kinetoplastpapers.bsky.social
Sporotrichoid leishmaniasis in psoriatic patient on biosimilar adalimumab therapy: an atypical clinical presentation pubmed.ncbi.nlm.nih.gov/41562438/
January 22, 2026 at 7:05 PM